ACIM
VRTX icon

Azimuth Capital Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Azimuth Capital Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.33M Sell
18,656
-86
-0.5% -$40.1K 0.31% 110
2025
Q4 		$8.5M Sell
18,742
-1,606
-8% -$692K 0.3% 112
2025
Q3 		$7.97M Sell
20,348
-684
-3% -$286K 0.29% 115
2025
Q2 		$9.36M Sell
21,032
-211
-1% -$97.2K 0.35% 106
2025
Q1 		$10.3M Sell
21,243
-898
-4% -$418K 0.41% 80
2024
Q4 		$8.92M Buy
22,141
+697
+3% +$323K 0.35% 98
2024
Q3 		$9.97M Sell
21,444
-105
-0.5% -$50.4K 0.39% 87
2024
Q2 		$10.1M Sell
21,549
-75
-0.3% -$32.6K 0.41% 72
2024
Q1 		$9.04M Sell
21,624
-20,421
-49% -$8.63M 0.37% 89
2023
Q4 		$17.1M Sell
42,045
-500
-1% -$185K 0.77% 42
2023
Q3 		$14.8M Sell
42,545
-584
-1% -$204K 0.73% 42
2023
Q2 		$15.2M Sell
43,129
-762
-2% -$257K 0.72% 42
2023
Q1 		$13.8M Buy
43,891
+108
+0.2% +$32.4K 0.68% 50
2022
Q4 		$12.6M Buy
43,783
+8,353
+24% +$2.55M 0.64% 49
2022
Q3 		$10.3M Sell
35,430
-147
-0.4% -$42.3K 0.56% 55
2022
Q2 		$10M Buy
+35,577
New +$9.52M 0.51% 65

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Azimuth Capital Investment Management's VRTX Position: Q1 2026 in Review

Azimuth Capital Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.46% in Q1 2026, selling an estimated $40.1K and leaving 18,656 shares worth $8.33M. The position accounts for 0.31% of the portfolio, ranked #110.

Azimuth Capital Investment Management first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $17.1M in Q4 2023. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Azimuth Capital Investment Management held 18,656 shares of Vertex Pharmaceuticals worth $8.33M as of Q1 2026.
  • Azimuth Capital Investment Management sold 86 Vertex Pharmaceuticals shares in Q1 2026, an estimated $40.1K.
  • Vertex Pharmaceuticals made up 0.31% of Azimuth Capital Investment Management's portfolio in Q1 2026, its #110 holding.
  • Azimuth Capital Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Azimuth Capital Investment Management's Vertex Pharmaceuticals position peaked at $17.1M in Q4 2023.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Azimuth Capital Investment Management's 13F filing for Q1 2026, filed 12 May 2026.